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A B S T R A C T
Background and Purpose: This study analyzed the prognostic signiﬁcance of the staging system based on the
metastatic Node Ratio (NR) compared with the TNM staging system in patients with colorectal cancer.
Methods: We reviewed the data of 444 patients who underwent colorectal resection for cancer between
January 2005 and December 2011. NR categories NR0 (0%), NR1 (1–19%) and NR2 (20%) were determined by
the best cut-off approach at log-rank test. To compare the prognostic power of the NR versus pN, we plotted
these different factors against the mortality estimates. Additionally, we evaluated the relationship between
these variables and the extent of lymphadenectomy.
Results: Both the NR and the pN classiﬁcation signiﬁcantly stratiﬁed patient outcomes (p < 0.0001), but the
NR system seems to better discriminate prognostic subgroups than the pN. Furthermore, NR is less dependent
on the extent of lymphadenectomy than pN.
Conclusions: NR is a simple and reliable tool to stratify survival of colorectal cancer patients and it seems to
have a higher prognostic power than the current pN system, because it is less dependent on the extent of
lymphadenectomy.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
The Tumour, Nodes, and Metastasis (TNM) staging system is a
worldwide benchmark for reporting the extent of malignant disease
and it is a major prognostic factor for predicting the outcome of
patients with cancer. 1
For colorectal cancer, the optimal staging system still represents
a matter of intense debate because in all the TNM editions, the
deﬁnition of lymph node status (N) has always been affected by the
extent of lymphnode dissection or node retrieval by pathologists. 2–5
With these premises, a pragmatic approach could be represented
by a lymph node staging system based on a classiﬁcation that
does not depend strictly on the extent of lymph node dissection.
Recently, several authors have discussed the possible signiﬁcance of
themetastatic Node Ratio (NR, the number ofmetastatic lymphnodes
related to the total number of dissected lymph nodes). NR has been
indicated as an optimal classiﬁcation criterion in predicting patient
survival and avoiding stage migration errors. 6
The oncological value of NR as a prognostic factor in colorectal
cancer survival seems to overcome the dependence of the lymphnode
number on anatomical features, surgical technique, surgeon skills,
and pathological analyses. 7–17
In the present study, more than 400 patients with colorectal
cancer were reviewed and the prognostic signiﬁcance of the NR was
evaluated in comparisonwith conventional N classiﬁcation according
to the TNM staging system. 1
2. Patients and methods
A total of 492 consecutive patients with colorectal carcinoma
underwent surgery between January 2005 and December 2011.
Eighteen patients (3.7%) were lost to follow up and 30 (6.1%) were
excluded because of incomplete data. The study is based on 444
patients (90.2%): 204 females (45.9%) and 240 males (54.1%) with
a mean±SD age of 67±11 years (median age: 65 years). Data were
collected from clinical charts and pathological exams: the factors
considered are speciﬁed in Table 1.
Pretreatment tumor stage was determined in all cases by con-
ventional imaging techniques, such as colonoscopy and chest and
abdominal CT scan. The colonic resections were performed via
conventional open or laparoscopic approach by different surgeons
with high experience in colorectal surgery.
2.1. Statistical analysis
The survival analysis was obtained from data collected during a
5-year follow-up program. The end-point of our study was cancer-
related death. Survivalwas considered from surgery to the last patient
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Table 1
Clinical and pathological data of the 444 patients with results of the univariate survival analysis
Variable No. of
patients




M 240 54.1 65.0
F 204 45.9 75.8
Age (years) 0.007
<65 193 80.0 79.9
 65 251 20.0 62.2
Comorbiditiesb N.S.
Yes 401 91.8 72.3
No 36 8.2 69.1
BMI (kg/m2)b N.S.
<27 145 67.4 69.8
27 70 32.6 77.9
Symptoms 0.080
Yes 337 75.9 68.4
No 107 24.1 72.3
CEA (U/l) b <0.001
<5ng/dl 70 63.0 93.1
5ng/dl 41 34.0 22.5
Surgical approach 0.011
Laparoscopic 228 51.4 79.2
Conversion 18 4.5 50.8
Open 198 44.6 79.2
pT <0.001
T1 19 4.3 66.3
T2 66 14.9 94.6
T3 321 72.3 69.4
T4 38 8.5 49.5
pN <0.001
N0 233 52.5 83.3
N1 117 26.3 68.0
N2 94 21.2 42.3
NR <0.001
NR0 233 52.5 83.3
NR1 134 30.2 63.7
NR2 77 17.3 43.3
Total nodes 0.100
<21 234 52.7 65.2
21 210 47.3 74.5
M <0.001
M0 374 84.2 80.2
M1 70 15.8 21.0
Grading <0.001
G1/ G2 368 82.9 76.3
G3 76 17.1 51.4
Lymphoinvasionb <0.001
Yes 142 32.6 56.1
No 293 67.2 78.6
Neuroinvasionb 0.004
Yes 51 11.6 51.8
No 386 88.1 72.0
Angioinvasionb <0.001
Yes 60 13.8 44.5
No 375 86.0 75.3
Postoperative complications 0.025
Yes 59 13.3 59.8
No 385 86.7 71.4
Adjuvant therapy 0.002
Yes 312 70.2 81.2
No 132 29.8 66.1
a Only p values 0.1 are listed explicitly. N.S., not signiﬁcant.
b Variable with missing data.
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(A) (B)
Fig. 1. (A) Survival curve according to pN. (B) Survival curve according to NR.
follow up or death (with patients censored for non cancer-related
death).
All variables were expressed as mean ± standard deviation (SD)
or median and range, as appropriate. Correlations between two
continuous variables were analyzed by the Pearson test. For some
tests continuous variables have been categorized according to the
median value or the literature suggestions. Five-year survival rates
were calculated according to the Kaplan–Meier method; the log-rank
test was used to assess the statistical difference between groups.
Multivariate analysis was performed using the Cox proportional
hazard model selected in backward stepwise regression, including
only the variables with p < 0.1 at log-rank test. For all the variables
the hazard ratio (HR) and the 95% conﬁdence interval (95%CI) were
calculated. The regression model was controlled by the goodness of
ﬁt tests.
In order to stratify the NR based prognosis, we used a cut-off of
20% (NR0=0%, NR1=1–19%, NR220%): this value derives from the
best discrimination obtained by the log-rank test applied to different
levels of NR. Values of p < 0.05 were considered signiﬁcant. The
statistical analysis was performed via SPSS (16th edition) software for
Windows©.
3. Results
After a median follow up of 26 months (31.5±20.8 months), 355 pa-
tients (80%) were alive; 89 had died, of whom 69 (69/89, 77.5%)
from colorectal cancer. The 5-year (cancer-related) survival rate was
70.2±5.8%.
We observed 162 (36.5%) right colon cancers, 27 (6.1%) trans-
verse colon, 59 (13.3%) left colon, 98 (22.1%) sigmoid colon,
49 (11.0%) rectum–sigmoid junction and 54 (12.2%) rectum. Only
6 patients (1.4%) presented multifocal localization.
Laparoscopic resections were performed in 228 cases (51.4%);
18 patients (4.5%) required conversion to open resection; 198 pa-
tients (44.6%) underwent conventional open resection. The mean
number of positive nodes was 2.1±4.0 and the mean number of total
removed nodes was 22.9±12.5.
Clinical and pathological data of the 444 patients with results of the
univariate survival analysis are shown in Table 1.
Figure 1 graphically demonstrates survival differences related to the
variables associated with lymph node staging (pN, NR).
Tables 2 and 3 show the results of multivariate analysis: in order
to overcome the multi-colinearity problem and to obtain an estimate
of reliability for pN and NR, we designed two different models of
multivariate analysis in which the lymph node status was included
separately as pN or NR.
Table 2






N2 <0.001 5.16 2.72 9.77
N1 0.003 2.63 1.39 4.99
N0 − 1 − −
Angioinvasion
Yes 0.011 1.92 1.16 3.17
No − 1 − −
Neuroinvasion
Yes 0.04 1.88 1.03 3.42
No − 1 − −
Lymphoinvasion
Yes 0.016 1.79 1.12 2.88
No − 1 − −
LL, lower limit; UL, upper limit.
Table 3






N2 <0.001 5.07 2.72 9.46
N1 0.013 2.34 1.2 4.58
N0 − 1 − −
Angioinvasion
Yes 0.014 1.90 1.14 3.15
No − 1 − −
Grading
G3 0.05 1.67 1.0 2.78
G1/G2 − 1 − −
Lymphoinvasion
Yes 0.041 1.63 1.02 2.62
No − 1 − −
LL, lower limit; UL, upper limit.
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Fig. 2. (A) Scatter plot for correlations betweenpositive nodes and total number of nodes removed. (B) Scatter plot for correlations betweenNRand total number of nodes removed.
(A) (B)
Fig. 3. (A) Survival curve of patients with <21 removed nodes, stratiﬁed according to NR. (B) Survival curve of patients with 21 removed nodes, stratiﬁed according to NR.
Moreover, we tested the relationship between lymphadenectomy
(numerically evaluated, as suggested by the TNMsystem) andnumber
of lymph node metastases and NR, respectively: we veriﬁed a
signiﬁcant strong direct correlation (r = 0.134, p = 0.005) between
number of lymph node metastases and total number of nodes
retrieved, without any evidence of signiﬁcant association (r = −0.069,
p = 0.150) between NR and number of lymph nodes removed (Fig. 2).
To further conﬁrm the independence between the NR and lym-
phadenectomy (evaluated this time according to a numeric cut-
off, as suggested for clinical practice), we stratiﬁed patients with
< or21 removed lymph nodes (ourmedian value) for NR subgroups:
NR is able to signiﬁcantly stratify survivals of both groups (Fig. 3).
A similar result was obtained using the cut-off of 12 nodes as
minimum number of lymph nodes to remove established by TNM
staging system (5-year survival rates in patients with <12 total nodes:
64.5% in NR1 cases and 41.2% in NR2 cases, p < 0.001; 5-year survival
rate in patients with12 total nodes: 59.1% in NR1 cases and 55.4% in
NR2 cases, p = 0.004). 1
4. Discussion
The last editions of UICC-TNM codiﬁed the minimum number of
lymph nodes to remove (12 in total) in order to accurately stage
the nodal involvement in colorectal cancer patients. 1 It is clear that
surgeons are not able to count the nodes during their procedure and
the number of removed nodes is necessarily a postoperative datum.
Hence, an ideal staging criterion for N status should not be affected
by the extent of lymphadenectomy. Node ratio has been proposed as
a solution to this problem. 6–17
Firstly, our study conﬁrmed that nodal involvement is among the
strongest prognostic factors for colorectal cancer patients: pN and NR
signiﬁcantly stratiﬁed patient survival (Fig. 1) andmultivariate analy-
sis showed that these indicators were both independent prognostic
factors. Actually, the hazard ratios for NR better discriminated
different groups than the HRs for pN (Tables 2, 3).
Secondly, we aimed to verify the relationship between NR and
extent of lymphadenectomy. Given that the current TNM staging
system categorizes patients with less than 12 examined nodes as
unclassiﬁable, 11,12 we investigated the potential independence of
NR from the number of removed nodes, possibly in order to stage
these patients. In our study, we demonstrated that NR is not entirely
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independent from the lymphadenectomy evaluated with numerical
criteria: in fact, NR has a decreasing trend (though not signiﬁcantly)
when the number of removed lymph nodes increases (Fig. 2).
However, this dependence is not signiﬁcant comparedwith the direct
dependence calculated for the pN staging: in fact, we signiﬁcantly
stratiﬁed according to NR categories also patients with a limited
lymphadenectomy (with <21 or <12 total nodes). This is a further
demonstration that the NR differs from pN: the number of positive
lymph nodes is the numerator of a ratio in which the denominator
is the total number of removed lymph nodes; thus, the NR can work
as a “reliever” of the factors that inﬂuence the number of lymph
nodes examined. 18–21 However, also the node ratio is not immune
to the stage migration phenomenon. Graphically, this risk could ﬁnd
a demonstration in Fig. 3a, where the survival curves of patients
with less than 21 lymph nodes examined are similar for the NR1
and NR2 groups; this is not the case for patients with more than
21 nodes removed, where the NR1 survival curve is closer to the
NR0 one. Speciﬁcally, the NR1 group of patients with less than 21
lymph nodes examined might include patients who with a more
extended lymphadenectomy would be classiﬁed in the group with
worse prognosis (NR2).
Finally, although this study has non-negligible limitations related
to its retrospective design and actuarial survival, our results are
consistent with the literature about the relevant prognostic impact of
NR (even though expressedwith different cut-offs). However, an open
problem is the correlation between NR and lymphadenectomy: if this
correlation will never be demonstrated, NR could appear as the best
prognostic factor for lymph node status because not susceptible of
stagemigration.On the contrary, if this correlationwill be proven beyond
doubt and a more extended lymphadenectomy (with a potentially higher
number of lymph nodes to be examined) will be performed reducing the
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